(Q37508022)

20 August 2017

1 reference

title

Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma (English)

1 reference

20 August 2017

0 references

0 references

Dale R Shepard

1

1 reference

20 August 2017

Jorge A Garcia

series ordinal

2

1 reference

20 August 2017

publication date

1 June 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

795-805

1 reference

20 August 2017

cites work

Cancer statistics, 2008

1 reference

The changing face of renal cell carcinoma pathology

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

21 January 2018

1 reference

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

21 January 2018

1 reference

Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload

21 January 2018

1 reference

Novel integrative approaches to the identification of candidate genes in hypertension

21 January 2018

1 reference

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure

21 January 2018

1 reference

Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse

21 January 2018

1 reference

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

21 January 2018

1 reference

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

21 January 2018

1 reference

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib

21 January 2018

1 reference

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

21 January 2018

1 reference

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

21 January 2018

1 reference

A reversible posterior leukoencephalopathy syndrome

21 January 2018

1 reference

Posterior reversible encephalopathy syndrome during sunitinib therapy

21 January 2018

1 reference

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

21 January 2018

1 reference

Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

21 January 2018

1 reference

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

21 January 2018

1 reference

Macrocytosis due to treatment with sunitinib

21 January 2018

1 reference

Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma

21 January 2018

1 reference

Gastrointestinal perforation due to bevacizumab in colorectal cancer

21 January 2018

1 reference

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

21 January 2018

1 reference

Bowel perforation after radiotherapy in a patient receiving sorafenib.

21 January 2018

1 reference

Managing side effects of angiogenesis inhibitors in renal cell carcinoma

21 January 2018

1 reference

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

21 January 2018

1 reference

Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions

21 January 2018

1 reference

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.29

1 reference

20 August 2017

1 reference